Analysts predict that Natera Inc (NASDAQ:NTRA) will announce $62.87 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Natera’s earnings. The highest sales estimate is $65.68 million and the lowest is $61.59 million. Natera posted sales of $53.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 16.9%. The business is scheduled to announce its next quarterly earnings report on Tuesday, March 12th.
According to Zacks, analysts expect that Natera will report full year sales of $253.49 million for the current financial year, with estimates ranging from $252.28 million to $256.37 million. For the next fiscal year, analysts anticipate that the company will report sales of $294.57 million, with estimates ranging from $275.00 million to $326.29 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Natera.
NTRA has been the topic of a number of research reports. ValuEngine downgraded Natera from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 9th. Cowen reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Natera in a research note on Friday, November 9th. Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. Finally, BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Friday, December 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $28.25.
Several institutional investors have recently made changes to their positions in the company. Prescott Group Capital Management L.L.C. boosted its holdings in shares of Natera by 18.6% in the 4th quarter. Prescott Group Capital Management L.L.C. now owns 147,628 shares of the medical research company’s stock worth $2,061,000 after purchasing an additional 23,200 shares during the period. First Trust Advisors LP purchased a new position in shares of Natera in the 4th quarter worth approximately $2,813,000. Jennison Associates LLC boosted its holdings in shares of Natera by 1.8% in the 4th quarter. Jennison Associates LLC now owns 3,706,873 shares of the medical research company’s stock worth $51,748,000 after purchasing an additional 65,025 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Natera in the 4th quarter worth approximately $1,311,000. Finally, Essex Investment Management Co. LLC boosted its holdings in shares of Natera by 3.2% in the 4th quarter. Essex Investment Management Co. LLC now owns 126,506 shares of the medical research company’s stock worth $1,766,000 after purchasing an additional 3,912 shares during the period. Hedge funds and other institutional investors own 87.50% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: What Does Beta Mean In Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.